The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects

被引:0
作者
Masaomi Takizawa
Dirk Cerneus
Ingrid Michon
Sanne Rijnders
Desiree van der Heide
John Meijer
Matthias Stoelzel
Yuichiro Sato
机构
[1] Astellas Pharma Inc.,
[2] Astellas Pharma Europe B. V.,undefined
[3] Astellas Pharma Inc.,undefined
来源
Advances in Therapy | 2020年 / 37卷
关键词
Anandamide; Fatty acid amide hydrolase; First-in-human study; Pharmacokinetics; Safety; Tolerability;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3878 / 3900
页数:22
相关论文
共 44 条
  • [1] Puffenbarger RA(2005)Molecular biology of the enzymes that degrade endocannabinoids Curr Drug Targets CNS Neurol Disord 4 625-631
  • [2] Lodola A(2015)Fatty acid amide hydrolase inhibitors: a patent review (2009–2014) Expert Opin Ther Pat 25 1247-1266
  • [3] Castelli R(2005)Retrograde signaling by endocannabinoids Handb Exp Pharmacol 168 367-383
  • [4] Mor M(2001)Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol Sci 22 565-572
  • [5] Rivara S(2010)International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB Pharmacol Rev 62 588-631
  • [6] Vaughan CW(2011) and CB BJU Int 108 1145-1149
  • [7] Christie MJ(2002)Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation Prostaglandins Leukot Essent Fatty Acids 66 101-121
  • [8] Schlicker E(2010)Cannabinoid receptors and their ligands Nat Neurosci 13 1265-1270
  • [9] Kathmann M(2006)Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism J Neurosci 26 13318-13327
  • [10] Pertwee RG(2019)Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain Front Mol Neurosci 11 487-483